IBAC · IB Acquisition Corp. Common Stock

Summary

On March 13, 2026, GNQ Insilico Inc. entered into a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company to collaborate on sales, marketing, development, and alliance activities for AI-driven drug discovery and precision medicine. The non-exclusive global agreement has an initial two-year term with extension option, integrating GNQ’s AI platforms with the partner’s consulting, cloud, and quantum computing capabilities.

Key takeaways

• GNQ Insilico Inc. signed Joint Initiative Agreement and Joint Marketing Attachment on March 13, 2026
• Agreement with Fortune 100 global technology company (Strategic Partner)
• Global territory, initial term of two years with mutual extension option
• Joint marketing of combined AI-powered platforms with consulting, cloud, and quantum computing
• Non-exclusive framework for joint business plans, customer leads in healthcare and life sciences